Authors
Andreas Katsimigas, Mikkel Werling, Casper M Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben-Dali, Mariam H Hleuhel, Christian Brieghel, Carsten U Niemann, Caspar da Cunha-Bang
Published in
British journal of haematology. Jul 01, 2026. Epub Jul 01, 2026.
Abstract
Diffuse large B-cell lymphoma (DLBCL) type Richter transformation (DLBCL-RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL-RT with or without previous CLL-directed therapy compared to dnDLBCL between 2002 and 2022. We included 6525 patients with dnDLBCL and 383 patients with DLBCL-RT, of whom 260 had Richter transformed treatment-naïve CLL (RT:TN-CLL) and 123 had Richter transformed treatment exposed CLL (RT:TE-CLL). Median time to next treatment or death (TTNTd) was 4.83 years, 1.43 years and 0.46 years for patients with dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively. Median overall survival (OS) following first-line treatment was 9.42, 5.22 and 0.72 years for dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively (p < 0.001). In a high-validity subcohort, OS did not differ significantly between RT:TN-CLL and dnDLBCL (median OS 9.85 years [CI: 9.16-10.70] for dnDLBCL, 6.07 years [CI: 4.23-not estimable] for RT:TN-CLL and 1.15 years [CI: 0.76-3.66] for RT:TE-CLL). In conclusion, patients with RT:TE-CLL had inferior TTNTd and OS compared to RT:TN-CLL and dnDLBCL. RT:TN-CLL demonstrated inferior TTNTd compared to dnDLBCL, but OS approached that of dnDLBCL. This indicates that for patients with RT:TN-CLL, chemoimmunotherapy may still be an effective modality, while patients with RT:TE-CLL need novel treatment options.
PMID:
42381485
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0